AVEO...note previous post I'm replying to...can ARLZ really go from under $1 to $6...?...sure anything can happen...
AVEO went from $0.70 to $3.00 since late June...IMHO AVEO is in no way deserving of its price(at this time); but the Market is giving them an early pass or something...whereas ARLZ is deserving of better than $1... The only way to trade these types of contrasts is "technical trading"...I can like both stock or have an opinion on one over the other...but I don't listen to me...I listen to technicals...
AVEO (T/$3-3.50) AVEO has made significant progress with its lead pipeline candidate, tivozanib. It is currently under review in the EU for the first-line treatment of advanced RCC. In Jun 2017, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of the candidate. A final response on the approval status of the candidate is expected in the third quarter of 2017. https://finance.yahoo.com/news/aveo-pharmaceuticals-aveo-q2-loss-142502771.html The company also announced achievement of enrollment target in a phase III study, TIVO-3, evaluating tivozanib, in June, ahead of its prior deadline of Aug 2017. Top-line data is expected in the first quarter of 2018. The study will compare tivozanib with Bayer’s BAYRY Nexavar in patients with refractory advanced renal cell carcinoma (RCC). The data from this study along with previously completed TIVO-1 study will support the regulatory application for approval of tivozanib in the U.S. as a first- and third-line treatment for RCC.
Daily
AVEO
AVEO went from $0.70 to $3.00 since late June...IMHO AVEO is in no way deserving of its price(at this time); but the Market is giving them an early pass or something...whereas ARLZ is deserving of better than $1... The only way to trade these types of contrasts is "technical trading"...I can like both stock or have an opinion on one over the other...but I don't listen to me...I listen to technicals...
AVEO (T/$3-3.50) AVEO has made significant progress with its lead pipeline candidate, tivozanib. It is currently under review in the EU for the first-line treatment of advanced RCC. In Jun 2017, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of the candidate. A final response on the approval status of the candidate is expected in the third quarter of 2017. https://finance.yahoo.com/news/aveo-pharmaceuticals-aveo-q2-loss-142502771.html The company also announced achievement of enrollment target in a phase III study, TIVO-3, evaluating tivozanib, in June, ahead of its prior deadline of Aug 2017. Top-line data is expected in the first quarter of 2018. The study will compare tivozanib with Bayer’s BAYRY Nexavar in patients with refractory advanced renal cell carcinoma (RCC). The data from this study along with previously completed TIVO-1 study will support the regulatory application for approval of tivozanib in the U.S. as a first- and third-line treatment for RCC.
Daily
AVEO
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
